RESEARCH ARTICLE

Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients

Aurore Goineau1☯, Loïc Campion2, Bénédicte d’Aillières1, Brigitte Vié3, Agnès Ghèsquière3, Guillaume Béra4, Didier Jaffres4, Guy de Laroche6, Nicolas Magné5, Xavier Artignan6, Jérôme Chamois6, Philippe Bergerot7, Etienne Martin8, Gilles Créhange8, Elisabeth Deniaud-Alexandre9, Xavier Buthaud10, Yazid Belkacémi11, Mélanie Doré12, Laure de Decker12, Stéphane Supiot12☯

1 Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, Angers, France, 2 Department of Statistics, Institut de Cancérologie de l’Ouest, Saint Herblain, France, 3 Department of Radiation Oncology, Clinique Armoricaine de Radiologie, St Brieuc, France, 4 Department of Radiation Oncology, Centre Hospitalier de Bretagne Sud, Lorient, France, 5 Department of Radiation Oncology, Institut de Cancérologie de Loire, St Priest en Jarez, France, 6 Department of Radiation Oncology, CHP St Grégoire, St Grégoire, France, 7 Department of Radiation Oncology, Clinique Mutualiste de l’Estuaire, St Nazaire, France, 8 Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France, 9 Department of Radiation Oncology, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France, 10 Department of Radiation Oncology, Centre Catherine de Sienne, Nantes, France, 11 Department of Radiation Oncology, CHU Henri Mondor, Créteil, France, 12 Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, Saint Herblain, France

☯ These authors contributed equally to this work.
* aurore.goineau@ico.unicancer.fr

Abstract

Introduction

Radiotherapy can diminish quality of life (QoL) for prostate cancer patients. Our objective was to evaluate the effect of radiotherapy on QoL in men aged 75 years or older treated with radiotherapy for a localized prostate cancer, and to identify predictors of reduced QoL.

Patients and methods

We prospectively administered a battery of geriatric (MNA, GDS, Get up and Go Test, CIRS-G, ADL, IADL, MMSE), toxicity (IPSS; IIEF 5), and QoL (QLQ C30) screening tests in 100 elderly patients before and two months after prostate cancer radiotherapy (NCT 02876237). Patients ≥ 75 years undergoing radiotherapy with a curative intent for localized prostate cancer with or without androgen deprivation therapy (ADL) were eligible for study inclusion. Correlations between patient-assessed QoL and tumor characteristics, radiotherapy treatment or CGA parameters were sought using the Fisher or the Mann and Whitney tests. Changes in QoL parameters over time were analyzed using the Wilcoxon signed-rank test.

Results

At study entry, scores for IADL impairments were present in 51%, reduced autonomy in activities of daily living in 16%, cognitive impairment found in 20%, depression-related
symptoms in 31%, and 66% of patients had significant co-morbidities. Eight percent were judged to be at risk of fall and 2% were found to be undernourished. Severely impaired (IPSS ≥ 20) urinary function was observed in 11.2% and 13.5% of patients before and two months after completion of radiotherapy respectively. Significantly decreased QoL (> 20 points) at two months after treatment was found in 13% of patients and a moderate but clinically relevant reduction (10 to 20 points) in 17% of patients. No tumor characteristic, treatment, or oncogeriatric parameter was predictive of reduced QoL following prostate cancer radiotherapy.

Conclusion

Despite sometimes markedly diminished oncogeriatric parameters, prostate cancer radiotherapy was generally well tolerated in these elderly patients. We found no predictive factor to determine which patients would experience impaired quality of life following radiotherapy.

Introduction

Prostate cancer mostly occurs in elderly men (aged ≥ 75 years) in whom it represents a major cause of impaired quality of life and is a leading cause of cancer mortality [1]. Localized prostate cancer in the elderly is mostly treated with androgen deprivation therapy (ADT) and/or radiotherapy, and surgery is only rarely recommended [2]. Although severe radiotherapy-induced toxicity is unusual in younger patients, occurring in fewer than 5% of them, curative radiotherapy is often believed to be less well tolerated in the elderly. Older patients tend to present with impaired urinary and digestive function that risk being by aggravated by radiotherapy. For this reason, only a minority of patients older than 75 with localized high-risk prostate cancer receive any local treatment. The majority receive palliative treatment (ADT or no therapy at all) [3], despite evidence showing significantly improved survival when radiotherapy is added to ADT [4,5].

The quality of life of patients undergoing intensity-modulated radiation therapy (IMRT) for prostate cancer often diminishes immediately after therapy [6,7], but most symptoms resolve within 6 months and long term quality of life is usually comparable to that prior to therapy [8–10]. Radiotherapy (and ADT) are particularly associated with increased asthenia and decreased social, physical and cognitive functioning at two months after treatment [6]. Retrospective studies suggest that prostate cancer radiotherapy is quite well tolerated in older patients [11,12], but despite the large burden of localized prostate cancer, prospective studies of quality of life after radiotherapy in this potentially fragile population are lacking.

The selection of elderly patients for risk-adapted oncology treatments remains a challenge for oncogeriatric study. Geriatric screening instruments offer one avenue of assistance to the clinician who wishes to orientate the fragile patient prior to any oncologic intervention [13]. Comprehensive Geriatric assessment (CGA) enables precise scoring of daily activities, risk of fall, undernutrition, depression, and comorbidities to help predict whether aggressive cancer treatments will be tolerated. Although CGA is largely used prior to medical interventions, such as chemotherapy [14] or ADT [15–17], specific studies of older prostate cancer patients undergoing radiotherapy are mostly retrospective, lack precise oncogeriatric evaluation [18–21] or focused on toxicity (assessed by physicians) and not on patient’s related quality of life [22].
We carefully analyzed the geriatric characteristics of a group of older patients and prospectively assessed toxicity and quality of life in order to be able to determine which factors might be predictive of poorly-tolerated radiotherapy.

**Patients and methods**

We recruited patients with localized prostate cancer aged 75 or more for whom a multidisciplinary tumour board had recommended local prostate radiotherapy with curative intent, alone, or combined with ADT, to a prospective multicenter cohort study (NCT 02876237). Patients were recruited by radiation oncologists during the first consultation, after the multidisciplinary tumor board and before starting radiation therapy. Patients undergoing salvage prostate bed radiotherapy following surgery were also included. There was no exclusion criteria regarding general conditions. The study was approved by the appropriate ethics committees, the Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé (CCTIRS) and the Commission Nationale Informatique et Liberté (CNIL). All patients gave consent for participating to the collection and analysis of data of this study.

All patients underwent a complete comprehensive Geriatric Assessment (CGA) by a geriatrician prior to initiation of radiotherapy. The past medical, personal and social history, current medication, body mass index, and home to study center distance were documented. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) [23], Activities of Daily Life (ADL) [24] and Instrumental Activities of Daily Life (IADL) [25], Mini Mental State Examination (MMSE) [26], mini Geriatric Depression Scale (GDS) [27], Mini Nutritional Assessment (MNA) [28], and the get up and go test (GUAGT) [29] were performed and the scores recorded. See Annexe 1 for details.

Clinical target volumes and organ-at-risk volumes were determined according to the GETUG (Groupe d’Etude des Tumeurs Urogenital, french group for genito-urinary tumors study) recommendations for prostate [30], prostatic bed [31] and pelvic lymph node [32] contouring. Radiotherapy was delivered to a total dose of 74.8–80 Gy in 34 to 40 fractions to the prostate or 66 Gy in 33 fractions to the prostatic bed. In high-risk patients, pelvic lymph nodes received 46–54.4 Gy in 23 to 34 fractions. Hypofractioned radiotherapy to the prostate (60 Gy in 20 fractions) was allowed in accordance with the PROFIT trial guidelines [33]. Dose constraints for the rectum and the bladder followed the Quantec recommendations [34,35].

Patients with an intermediate prognosis according to D’Amico’s classification were eligible for 3–6 months of concurrent and adjuvant hormonal therapy, which was extended to 2 to 3 years in high risk patients [36]. ADT was to be administered prior to or on the first day of radiotherapy.

Patients completed the International Prostate Symptom Score (IPSS), the International Index of Erectile Function (IIEF-5), the core and prostate cancer–specific modules of the European Organization for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires (QLQ-C30 version 3.0) at the first consultation (before radiotherapy) and at two months after treatment. We did not monitor quality of life during radiotherapy because very different radiotherapy protocols were used (between 20 to 40 fractions in 4 and 8 weeks), instead focusing on early (2 months) assessment after radiotherapy. Items were combined according to EORTC criteria into several scales ranging from 1 to 100. The higher the score for global health and function, the better the QoL; the higher the score for symptoms, the poorer the QoL.

Correlations between patient-assessed QoL, their treatment, and CGA parameters were sought using the Fisher test for linear association (categoric variables) or the Mann and Whitney test (continuous variables). The significance threshold was \( p < 0.05 \), except for changes in
QoL from baseline. A 10-point change in QoL was considered to be moderate but clinically relevant, severe for a 20-point change in score, and statistically significant if \( p < 0.01 \) [37,38]. These changes in QoL parameters over time (decrease on functional scoring and increase on symptoms scoring) were analyzed using the Wilcoxon signed-rank test.

**Results**

**Assessment at study entry**

One hundred patients presenting with intermediate (49%) or high-risk prostate cancer (48%) were recruited in 11 different cancer centers (Table 1). Their median age was 77.5 years (mean 78.4; range 75–89). The median distance between the patient’s home and radiotherapy center was 28 km (mean 32 km; range 4–147). The ADT was administered in 50% of patients. Severely (IPSS 20–35) or moderately impaired urinary function (IPSS 8–19) was observed in 11.2% (10/89) and 44.9% (40/89) of patients respectively. Among 78 patients who responded to the IIEF questionnaire which assesses sexual activity and erectile function, sexual activity was present in 26 patients (33.3%), among whom eight (10.3%) experienced normality or only minor dysfunction (IIEF 16–25), nine (11.5%) moderate dysfunction (IIEF 11–15), and nine (11.5%) severe dysfunction (IIEF 5–10). The CIRS-G revealed comorbidity in 66/100 patients, with 51/100 of patients presenting moderate to severe cardiovascular comorbidities. A GDS score \( \geq 1 \) revealed depressive symptoms in 31/100 of patients. The activities of daily life (ADL score \( > 6 \)) and Instrumental Activities of Daily Life (IADL score \( > 7 \)) were impaired in 16/100 and 51/100 of patients respectively. Cognitive disorders (MMSE \( < 27 \)) were revealed in 20/100 of patients. The calculated risk of fall (GUAGT \( < 0 \)) was 8/100 and undernutrition (MNA \( \leq 17 \)) was found in 2/100 of patients.

**Assessment following radiotherapy**

Two months after radiotherapy had concluded urinary function was assessed using the IPSS questionnaire in 89 patients. Severely (IPSS 20–35), moderately (IPSS 8–19), or only mildly impaired or normal function (IPSS \( < 8 \)) was noted in 13.5% (12/89), 44.9% (40/89) and 41.6% (37/89) of patients respectively. Similarly, among 71 patients who responded to a further IIEF questionnaire, sexual activity was maintained in 17 patients (23.9%). Among these, two (2.8%) experienced normal or only minor dysfunction (IIEF 16–25), four (5.6%) moderate impairment (IIEF 11–15) and eleven (15.5%) severe impairment (IIEF 5–10) of erectile function. We analyzed self-reported QoL following radiotherapy in 100 patients (see Fig 1 and Table 2). According to the core QoL questionnaire, general QoL was moderately decreased (loss of 10 to 20 points) in 17 patients (17%) and markedly decreased (loss \( \geq 20 \) points) in another 13 patients (13%). On an individual basis (Table 2), the most frequent important (variation \( > 20 \) points) QoL alterations were diarrhea (21 patients), constipation (14), role functioning (20), fatigue (18) dyspnea (17) and insomnia (17).

We then analyzed mean score comparisons of each item on the QLQ C30 questionnaire between baseline and two months (Fig 2a and 2b). Significant (\( p < 0.01 \)) impairment in role (mean loss -9, \( p = 0.0001 \)) and social functioning (mean loss -4.9, \( p = 0.0044 \)) was observed at two months compared with baseline. On the symptom scales, only fatigue (mean increase +4.6, \( p = 0.0029 \)) was significantly increased at two months.

**Predictive factors for impaired patient-reported outcomes**

We wished to determine whether any clinical parameter or geriatric score was predictive for impaired QoL parameters (Table 3). No parameter was found significantly predictive for a
deterioration in general QoL. Better QoL at baseline was associated with more moderate alterations in QoL at two months after radiotherapy had concluded (p = 0.012).

**Discussion**

The decision as to whether to recommend local treatment for prostate cancer in the elderly remains challenging, and prospective data on the tolerability of radiotherapy in this population were lacking. Our comprehensive and systematic evaluation of a large representative cohort confirms that a substantial proportion of these patients are indeed at risk of fatigue and

Table 1. Patient characteristic N = 100.

| Age       | %  |
|-----------|----|
| 75–79     | 72 |
| 80–85     | 24 |
| ≥ 85      | 2  |

| BMI        |    |
|------------|----|
| underweight (<18) | 2 |
| normal (18–25)     | 27 |
| overweight (25–30)  | 50 |
| obesity (>30)      | 21 |

| Number of medications |    |
|-----------------------|----|
| 0–3                   | 58 |
| > 3                   | 42 |

| Distance to radiotherapy center |    |
|---------------------------------|----|
| < 30 km                         | 54 |
| 30 à 60 km                      | 27 |
| ≥ 60 km                         | 19 |

| Clinical stage |    |
|----------------|----|
| low            | 3  |
| Intermediate   | 49 |
| high           | 48 |

| Geriatric problems |    |
|--------------------|----|
| Depression         | 31 |
| Impaired GUAGT     | 8  |
| Denutrition        | 2  |
| Comorbidities      | 66 |
| ADL impairment     | 16 |
| IADL impairment    | 51 |
| Cognitive impairment | 20 |

| Radiotherapy                  |    |
|-------------------------------|----|
| prostate                      | 76 |
| prostate bed                  | 24 |

| ADT                            |    |
|-------------------------------|----|
| yes                           | 50 |
| no                            | 50 |

BMI: body mass index
ADL: activities of daily life
IADL: instrumental activities of daily life
ADT: androgen deprivation therapy

https://doi.org/10.1371/journal.pone.0194173.t001
Fig 1. Individual changes in global QoL. Questions 29 and 30 in EORTC QLQ C30 questionnaires enable to calculated a score (from 0 to 100) for global QoL. Variations of this score before and 2 months after radiotherapy are reported here for each patient. There is an important decrease of QoL (≥ 20 points) for 13 patients and a moderate decrease in QoL (10 to 20 points) in 17 patients.

Table 2. Variation of quality of life and symptoms parameters N = 100.

|                           | Variation 10–20 (%) | Variation ≥ 20 (%) | Variation ≥ 10 (%) |
|---------------------------|---------------------|--------------------|--------------------|
| Global Health             | 17                  | 13                 | 30                 |
| Physical functioning      | 5                   | 9                  | 14                 |
| Role functioning          | 12                  | 20                 | 32                 |
| Emotional functioning     | 7                   | 4                  | 11                 |
| Cognitive functioning     | 16                  | 5                  | 21                 |
| Social functioning        | 16                  | 12                 | 28                 |
| Fatigue                   | 22                  | 18                 | 40                 |
| Nausea / Vomiting         | 1                   | 3                  | 4                  |
| Pain                      | 12                  | 11                 | 23                 |
| Dyspnoea                  | 0                   | 17                 | 17                 |
| Insomnia                  | 0                   | 17                 | 17                 |
| Appetite loss             | 0                   | 11                 | 11                 |
| Constipation              | 0                   | 14                 | 14                 |
| Diarrhoea                 | 0                   | 21                 | 21                 |
| Financial difficulties    | 0                   | 4                  | 4                  |
impaired QoL following radiotherapy. However, our most important finding is that despite numerous comorbidities and frequently impaired geriatric parameters, more than 70% of older patients undergoing radiotherapy maintain their overall QoL immediately after completion of radiotherapy. No geriatric, patient or treatment-related parameters were predictive of impaired QoL following radical radiotherapy.

The majority of these elderly patients presented with impaired geriatric parameters. More than half of our patients about to undergo radiotherapy had some pre-existing restriction in Figure 2. For each item of QLQ C30 questionnaire, we compare mean score before and 2 months after radiotherapy. For functional scales (Fig 2a), a high score is related to better QoL and for symptoms scores (Fig 2b), high score is related to high symptoms and worth QoL. Statistically significant variations.

https://doi.org/10.1371/journal.pone.0194173.g002
|                                | No QoL decrease > 10 points (n = 70) | QoL decrease > 10 points (n = 30) | p   |
|--------------------------------|-------------------------------------|-----------------------------------|-----|
| Age                            | 78 [75–89]                          | 77 [75–88]                        | 0.933 |
| Distance                       | 28 [4–147]                          | 19 [5–85]                         | 0.687 |
| BMI                            | 27.4 [20.5–42.9]                    | 25.9 [19.8–34.9]                  | 0.187 |
| Number of medications          | 3 [0–6]                             | 2 [0–6]                           | 0.873 |
| QLQ-C30 T0                     | 75.0 [0–100]                        | 83.3 [50.0–100]                   | 0.012 |
| Clinical stage                 |                                     |                                   | 0.721 |
| Low                            | 3                                   | 0                                 |      |
| Intermediate                   | 33                                  | 15                                |      |
| High                           | 34                                  | 15                                |      |
| Radiotherapy                   |                                     |                                   | 0.153 |
| prostate                       | 56                                  | 20                                |      |
| prostatic bed                  | 14                                  | 10                                |      |
| ADT                            |                                     |                                   | 0.614 |
| No                             | 33                                  | 16                                |      |
| Yes                            | 36                                  | 14                                |      |
| Depression                     |                                     |                                   | 0.422 |
| No                             | 50                                  | 19                                |      |
| Yes                            | 20                                  | 11                                |      |
| Risk of fall                   |                                     |                                   | 0.699 |
| No                             | 55                                  | 24                                |      |
| Yes                            | 5                                   | 3                                 |      |
| Denutrition                    |                                     |                                   | 0.3  |
| No                             | 70                                  | 29                                |      |
| Yes                            | 0                                   | 1                                 |      |
| Comorbidities                  |                                     |                                   | 1    |
| No                             | 24                                  | 10                                |      |
| Yes                            | 46                                  | 19                                |      |
| Urinary symptoms               |                                     |                                   | 0.576 |
| Light                          | 25                                  | 14                                |      |
| Moderate                       | 29                                  | 11                                |      |
| High                           | 8                                   | 2                                 |      |
| ADL impairments                |                                     |                                   | 0.138 |
| No                             | 56                                  | 28                                |      |
| Yes                            | 14                                  | 2                                 |      |
| IADL impairments               |                                     |                                   | 1    |
| No                             | 34                                  | 15                                |      |
| Yes                            | 36                                  | 15                                |      |
| Cognitive impairment           |                                     |                                   | 0.749 |
| No                             | 59                                  | 27                                |      |
| Yes                            | 10                                  | 3                                 |      |
| Urinary symptoms at 2 months   |                                     |                                   | 0.177 |
| Mild                           | 25                                  | 12                                |      |
| Moderate                       | 31                                  | 9                                 |      |
| Severe                         | 6                                   | 6                                 |      |

https://doi.org/10.1371/journal.pone.0194173.t003
Moreover, two thirds of patients presented with comorbidities, especially cardiovascular comorbidities, which may affect ADT tolerance [36]. Unsuspected memory loss problems were discovered in one in five patients, and depression in almost one in three patients, which may also be aggravated by ADT [39]. These fragilities were usually found in metastatic cancer patients [40,41]. This underlines the utility of CGA prior to initiation of curative radiotherapy treatment, in order to provide appropriate overall care in this vulnerable population. The vulnerabilities of geriatric prostate cancer patients undergoing radiotherapy differ from those of metastatic patients undergoing chemotherapy [42]. Numerous studies have insisted upon the importance of nutritional status prior to drug administration, both for the tolerability of chemotherapy, and survival [43,44]. In our study, malnutrition was practically absent. Geriatric screening questionnaires place considerable weight on the evaluation of the nutritional status: on the G8 three questions out eight relate to nutrition [45]. Similarly impaired GUAGT is often sought by geriatricians [43] but was found in fewer than 10% of our patients. This suggests that a screening tool like G8 may be insufficient to fully evaluate the occult vulnerabilities in these elderly patients and that fuller CGA is needed, in accordance with other recent findings [22].

Despite impaired geriatric parameters, radiotherapy was well tolerated and the QoL maintained in a large proportion of patients. Urinary function was overall well preserved following radiotherapy (severe urinary symptoms in 11.2% of patients prior to radiotherapy compared with 13.5% after). This result contrasts with previous studies showing that increased age (>70) is a risk factor for increased urinary toxicity [46,47]. Longer follow-up is needed to fully assess long-term urinary toxicity. Important (>20 points) acute diarrhea occurred in 21% of patients. Older patients are also at higher risk of digestive toxicity [48,49]. In a minority of patients (less than 20%), radiotherapy potentially increased fatigue, which consequently decreased social and leisure interactions. The source of fatigue during radiotherapy is multiple: comorbidities, transportation to the radiotherapy center, nocturia or ADT. Fatigue is very common in men with prostate cancer, particularly in those receiving ADT, and is a common side effect of prostate cancer radiotherapy [50,51], but whether this fatigue is greater in older patients remains unproven.

Despite acute toxicity, overall QoL was maintained or improved in 70% of patients and only 13% of patients complained of severely (>20 points) decreased QoL at two months. These favourable results are similar to studies in younger patients, where radiotherapy combined with 6-months of androgen-depriving therapy did not profoundly alter physical or mental health as compared to active monitoring [52]. We previously evaluated longitudinal QoL following IMRT in a younger population (median age 73, range [50–80]), and found a similar pattern where quality of life was moderately impaired at two months but then returned to baseline after six months [6,9]. Other studies have also showed moderate but transient impaired QoL immediately after radiotherapy in younger patients [10,53,54]. However, more patients experienced moderately (17% vs 5.2%) or markedly (13% vs 10.5%) impaired overall QoL in this geriatric series than in our younger patient series. The impact of age on impairment of QoL remains an open question.

We hypothesized that a CGA prior to the initiation of radiotherapy, together with comprehensive collection of patient- and treatment-related data would enable us to predict decreased QoL at two months after radiotherapy had ended. Neither baseline oncogeriatric parameters, patient or tumor characteristics, distance to radiotherapy center, nor the use of ADT were correlated to severely (>20 points) or moderately (>10 points) impaired QoL. This might be explained by a quite limited sample and/or by the low number of patients experiencing decreased QoL. Some authors showed that higher levels of comorbidity diseases were predictive of decreased long-term global QoL following radiotherapy and ADT [55]. Others confirms
our findings with difficult for CGA outcomes to predict significant acute radiotherapy toxicity [22]. We will pursue the analysis over a longer follow-up period and repeat CGA during follow up to evaluate the impact of geriatric characteristics on subsequent QoL following radiotherapy.

The generalizability of our study may be limited by a potential selection bias. In France, all patients who are candidates for radical radiotherapy treatment must be discussed at a multidisciplinary board meeting. During these meetings, the urologists often propose active monitoring or ADT for very fragile older patients. Considering the potential selection bias, we asked the investigators in each center. We can summarise as follow: about 5% of the patients we considered too frail for radiotherapy during multidisciplinary tumor board. Patients over 75 represent between 40% and 50% of all patients treated by radiotherapy for a localised prostate cancer. Successful recruitments were very different between the eleven centers, between 100% to 50%, and patient’s refusal was often due to important distances between home and radiotherapy center. Our patient population does not therefore reflect the general population of older men with prostate cancer. However, our study was not restricted to teaching hospitals (where tertiary referral may produce an atypical patient population) and more importantly, our CGA revealed that a large number of patients were considered to have CGA impairments. Our study is therefore reasonably representative of the population of patients whose life expectancy suggests that they may benefit from radical radiotherapy. Our study was restricted to acute toxicity and early evaluation of reported outcomes. We focused on an early time point (two months after treatment) because our previous study showed that QoL worsened immediately following radiotherapy but returned to baseline 18 months after completion of IMRT. However, delayed intestinal toxicity affecting QoL may occur years after completion of radiotherapy [52]. We therefore need to validate our results after longer follow-up. Another potential limitation of our study is that the CGA may have revealed treatable problems whose correction prior to radiotherapy may have reduced the impact of this treatment on QoL. To avoid this bias, a clinical trial randomizing CGA should be performed, as has been done in lung cancer [56].

Conclusion
Localized prostate cancer of older men is a common clinical situation and the role of radical radiotherapy is controversial. Most patients are currently treated by active monitoring or ADT only. Our study is the first to extensively evaluate geriatric parameters prior to initiation of radiotherapy and longitudinally assess for QoL parameters following treatment. Our data suggest that QoL is mostly well conserved soon after radiotherapy, with or without ADT, even in this often debilitated patient population. This means that if there is a reasonable prospect that local radiotherapy will enhance the patient’s life expectancy, the fear of iatrogenic decreased QoL need not inhibit the decision to treat. An extensive CGA prior to initiation of radiotherapy can reveal comorbidities that may worsen after radiotherapy combined with ADT. We found no particular predictive factors for which older patients were most at risk of decreased QoL following radiotherapy. Further evaluation of long-term QoL is needed.

Supporting information
S1 Dataset. Full dataset for the study.
(XLSX)

S1 Questionnaires. Questionnaires and scoring (french version).
(DOC)
Acknowledgments
Funded by Unité de Concertation en Onco-Gériatrie (UCOG) des Pays-de-la-Loire.

Author Contributions
Conceptualization: Aurore Goineau, Stéphane Supiot.

Data curation: Aurore Goineau, Loïc Campion.

Investigation: Aurore Goineau, Bénédicte d’Aillières, Brigitte Vié, Agnès Ghesquière, Guillaume Béra, Didier Jaffres, Guy de Laroche, Nicolas Magné, Xavier Artignan, Jérôme Chamois, Philippe Bergerot, Etienne Martin, Gilles Créhange, Elisabeth Deniaud-Alexandre, Xavier Buthaud, Yazid Belkacémi, Mélanie Doré, Laure de Decker, Stéphane Supiot.

Methodology: Loïc Campion.

Project administration: Aurore Goineau, Stéphane Supiot.

Supervision: Aurore Goineau, Stéphane Supiot.

Writing – original draft: Aurore Goineau.

Writing – review & editing: Aurore Goineau, Stéphane Supiot.

References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer Oxf Engl 1990. 2013; 49: 1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027 PMID: 23485231
2. Droz J-P, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014; 15: e404–414. https://doi.org/10.1016/S1470-2045(14)70018-X PMID: 25079103
3. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011; 29: 235–241. https://doi.org/10.1200/JCO.2010.30.2075 PMID: 21135285
4. Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat Rev Urol. 2015; 12: 193–204. https://doi.org/10.1038/nrurol.2015.50 PMID: 25800395
5. Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol. 2015; 33: 716–722. https://doi.org/10.1200/JCO.2014.57.2743 PMID: 25559808
6. Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, et al. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010; 77: 1053–1059. https://doi.org/10.1016/j.ijrobp.2009.06.024 PMID: 19880259
7. Yoshimura K, Kamoto T, Nakamura E, Segawa T, Kamba T, Takahashi T, et al. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer Prostatic Dis. 2007; 10: 288–292. https://doi.org/10.1093/ijpcan.4500823 PMID: 17160068
8. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2006; 358: 1250–1261. https://doi.org/10.1056/NEJMoa074311 PMID: 18354103
9. Goineau A, Marchand V, Rigaud J, Bourdin S, Rio E, Campion L, et al. Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer. Radiat. 2013; 8: 53. https://doi.org/10.1186/1748-717X-8-53 PMID: 23510499
10. Lips IM, van Gils CH, van der Heide UA, Kruger AEB, van Vulpen M. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int. 2009; 103: 762–767. https://doi.org/10.1111/j.1464-410X.2008.08117.x PMID: 18990145
11. Nguyen TD, Azria D, Brochon D, Poortmans P, Miller RC, Scandolaro L, et al. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer
network. Crit Rev Oncol Hematol. 2010; 74: 66–71. https://doi.org/10.1016/j.critrevonc.2009.04.004 PMID: 19419885

12. Pignon T, Horiot JC, Bolla M, van Poppel H, Bartelink H, Roelofs F, et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997; 42: 107–120. PMID: 9106920

13. Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PloS One. 2014; 9: e115060. https://doi.org/10.1371/journal.pone.0115060 PMID: 25503576

14. Gerritse FL, Meulenberg HJ, Roddhart JML, van der Velden AMT, Blaasse RJB, Smilde TJ, et al. Analysis of docetaxel therapy in elderly (≥70years) castration resistant prostate patients enrolled in the Netherlands Prostate Study. Eur J Cancer Oxf Engl 1990. 2013; https://doi.org/10.1016/j.ejca.2013.06.008 PMID: 23849828

15. Lee CE, Kilgour A, Lau YKJ. Efficacy of walking exercise in promoting cognitive-psychosocial functions.

16. Dale W. “Staging the aging” when considering androgen deprivation therapy for older men with prostate cancer. J Clin Oncol. 2009; 27: 3420–3422. https://doi.org/10.1200/JCO.2009.22.9104 PMID: 19506150

17. Thorsen L, Nilsen TS, Raastad T, Courneya KS, Skovlund E, Fosså SD. A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design. BMC Cancer. 2012; 12: 123. https://doi.org/10.1186/1471-2407-12-123 PMID: 22458865

18. Bekelman JE, Mitra N, Elstawitho J, Liao K, Sunderland R, Yeboa DN, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e325–334. https://doi.org/10.1016/j.ijrobp.2011.02.006 PMID: 21498008

19. Namiki S, Ishidoya S, Kawamura S, Tochigi T, Arai Y. Quality of life among elderly men treated for prostate cancer. J Urol. 2002; 168: 1323–1327. https://doi.org/10.1016/S0022-5347(05)00462-9 PMID: 12204493

20. Nanda A, Chen M-H, Moran BJ, Bracciforte MH, Dosoretz D, Salenius S, et al. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 77: 147–152. https://doi.org/10.1016/j.ijrobp.2009.04.085 PMID: 19744800

21. Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol. 2014; 32: 2523–2530. https://doi.org/10.1200/JCO.2014.55.1531 PMID: 25071137

22. Osborne GEC, Appleyard SA, Gilbert DC, Jones CI, Lorimer C, Villanueva M, et al. Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical Radiotherapy. Clin Oncol R Coll Radiol G B. 2017; 29: 609–616. https://doi.org/10.1016/j.clon.2017.05.003 PMID: 28592379

23. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41: 237–248. PMID: 15947110

24. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. JAMA. 1963; 185: 914–919. PMID: 14044222

25. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. The Gerontologist. 1969; 9: 179–186. PMID: 5349366

26. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189–198. PMID: 1202204

27. Clément JP, Nassif RF, Léger JM, Marchan F. [Development and contribution to the validation of a brief French version of the Yesavage Geriatric Depression Scale]. L’Encéphale. 1997; 23: 91–99. PMID: 9264935

28. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med. 2002; 18: 737–757. PMID: 12608501

29. Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the “get-up and go” test. Arch Phys Med Rehabil. 1986; 67: 387–389. PMID: 3487300

30. Beckendorf V, Guerif S, Le Prisé É, Cosset J-M, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011; 80: 1056–1063. https://doi.org/10.1016/j.ijrobp.2010.03.049 PMID: 21147514

31. Carrie C, Hasbini A, de Laroché G, Richaud P, Guerif S, Latorzef F, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical
prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016; 17: 747–756. https://doi.org/10.1016/S1470-2045(16)00111-X PMID: 27160475

32. Sargos P, Guerif S, Latorzeff I, Hennequin C, Pommier P, Lagrange J-L, et al. Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU). Cancer Treat Rev. 2015; 41: 814–820. https://doi.org/10.1016/j.ctrv.2015.10.005 PMID: 26508669

33. PROFIT—Prostate Fractionated Irradiation Trial—ClinicalKey [Internet]. [cited 24 Aug 2016]. https://www.clinicalkey.fr/#/content/clinical_trial/24-s2.0-NCT00304759

34. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010; 76: S123–129. https://doi.org/10.1016/j.ijrobp.2009.03.078 PMID: 20171506

35. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010; 76: S116–122. https://doi.org/10.1016/j.ijrobp.2009.02.090 PMID: 20171505

36. Martin JM, Supiot S, Berthold DR. Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs. 2011; 71: 1019–1041. https://doi.org/10.2165/11591500-000000000-00000 PMID: 21668040

37. Osoba D, Rodrigues J, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16: 139–144. https://doi.org/10.1200/JCO.1998.16.1.139 PMID: 9440735

38. Guren MG, Dueland S, Skovlund E, Fossà SD, Poulsen JP, Tveit KM. Quality of life during radiotherapy for rectal cancer. Eur J Cancer Oxf Engl 1990. 2003; 39: 587–594.

39. Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016; 34: 1905–1912. https://doi.org/10.1200/JCO.2015.64.1969 PMID: 27069075

40. Aparicio T, Jouve J-L, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, et al. Geriatric factors predicting chemotherapy feasibility: ancillary results of FFCD 2001–02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013; 31: 1464–1470. https://doi.org/10.1200/JCO.2012.42.9894 PMID: 23467011

41. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011; 29: 3636–3642. https://doi.org/10.1200/JCO.2010.31.0664 PMID: 21709194

42. Terret C, Albrand G, Droz JP. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer. 2004; 2: 236–240. PMID: 15072607

43. Soubeyran P, Fonck M, Blanc-Bisson C, Blanc J-F, Ceccaldi J, Mertens C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012; 30: 1829–1834. https://doi.org/10.1200/JCO.2011.35.7442 PMID: 22508806

44. Blanc-Bisson C, Fonck M, Rainfray M, Soubeyran P, Bourdel-Marchasson I. Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol. 2008; 67: 243–254. https://doi.org/10.1016/j.critrevonc.2008.04.005 PMID: 18554922

45. Liuu E, Canou Poirine F, Pourriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol. 2014; 5: 11–19. https://doi.org/10.1016/j.jgo.2013.08.003 PMID: 24484713

46. Wortel RC, Incrocio L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S, et al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Int J Radiat Oncol Biol Phys. 2016; 95: 680–689. https://doi.org/10.1016/j.ijrobp.2016.01.031 PMID: 27055398

47. Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A, et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys. 2012; 82: 191–199. https://doi.org/10.1016/j.ijrobp.2010.09.027 PMID: 21109361

48. Longobardi B, Berardi G, Fiorino C, Alongi F, Cozzarini C, Deli A, et al. Anatomical and clinical predictors of acute bowel toxicity in whole pelvis irradiation for prostate cancer with Tomotherapy. Radiother Oncol. 2011; 101: 460–464. https://doi.org/10.1016/j.radonc.2011.07.014 PMID: 21864924

49. Perna L, Alongi F, Fiorino C, Broggi S, Cattaneo Giovanni M, Cozzarini C, et al. Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy. Radiother Oncol. 2010; 97: 71–75. https://doi.org/10.1016/j.radonc.2010.02.025 PMID: 20307910
50. Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer. 2013; 21: 1761–1771. https://doi.org/10.1007/s00520-013-1751-5 PMID: 23455492

51. Lilleby W, Stensvold A, Dahl AA. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer. Acta Oncol. 2016; 55: 807–813. https://doi.org/10.3109/0284186X.2015.1127417 PMID: 26959297

52. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016; https://doi.org/10.1056/NEJMoa1606221 PMID: 27626365

53. Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X, Scardino PT. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol. 2016; 118: 85–91. https://doi.org/10.1016/j.radonc.2015.11.035 PMID: 26780999

54. Kerleau C, Guizard A-V, Daubisse-Marliac L, Heutte N, Mercier M, Grosclaude P, et al. Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. Eur J Cancer Oxf Engl 1990. 2016; 63: 143–153. https://doi.org/10.1016/j.ejca.2016.05.020 PMID: 27318002

55. Geinitz H, Thamm R, Scholz C, Heinrich C, Prause N, Kerndl S, et al. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer. Strahlenther Onkol. 2010; 186: 46–52. https://doi.org/10.1007/s00066-009-2023-7 PMID: 20082188

56. Gajra A, Loh KP, Hurria A, Muss H, Maggiore R, Dale W, et al. Comprehensive Geriatric Assessment-Guided Therapy Does Improve Outcomes of Older Patients With Advanced Lung Cancer. J Clin Oncol; https://doi.org/10.1200/JCO.2016.67.5926 PMID: 27551131